Cian Healthcare has formally exited its Corporate Insolvency Resolution Process, ushering in a new management team and a significant capital restructuring. While the company has wiped out promoter equity and brought in a new Successful Resolution Applicant, investors face hurdles including widening operating losses and serious auditor qualifications regarding financial controls and inventory valuation. The company also recently revised its market lot size to 137 shares to boost liquidity.
Cian Healthcare Posts FY26 Results Post-Insolvency Exit
Revenue from operations stood at Rs 28.30 crore for FY 2025-26, down from Rs 30.88 crore in FY 2024-25. The company reported an expanded loss after tax of Rs 21.02 crore, compared to a loss of Rs 19.66 crore in the previous fiscal year.
Reader Takeaway: New management transition follows successful insolvency resolution, but auditor warnings on internal controls remain a key risk.
What just happened
Cian Healthcare has concluded its Corporate Insolvency Resolution Process (CIRP) following an NCLT-approved plan. The company has underwent a major capital overhaul, extinguishing former promoter shares and issuing new equity to the Successful Resolution Applicant (SRA) and public shareholders. A new board has been installed as of February 1, 2026, with Rajesh Jain taking over as Managing Director and Manish Goswami as Chairperson.
Why this matters
This marks a fresh start for the company under new ownership. However, the latest annual report contains a qualified audit opinion, signaling significant concerns regarding the accuracy of its financial reporting. Auditors flagged issues with inventory valuation differences of Rs 13.54 crore, the lack of physical verification for assets, and insufficient evidence for a Rs 27.81 crore provision for loans and advances.
Risks to watch
The company continues to face operational pressure, with EBITDA losses widening to Rs 5.27 crore from Rs 2.77 crore. Additionally, its subsidiary, Dr. Smith's Biotech Private Limited, remains in its own CIRP process, casting a shadow over the group's consolidated financial health. The auditor's inability to verify internal audit trails further complicates the transparency of the current financial statements.
What to track next
Shareholders should monitor the upcoming 23rd Annual General Meeting on September 29, 2026, where the appointment of M/s Rasool Singhal & Co. as new statutory auditors will be finalized. The key focus for the market will be the new management's ability to remediate the qualified internal control weaknesses and reverse the trend of operating losses.